Xenon Pharmaceuticals Inc
XENE
Market Cap$2.21B
Close$
$1.72
94.4% downside
Current Fair Value
94.4% downsideOvervalued by 94.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.21 Billion |
|---|---|
| Enterprise Value | $2.11 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.01 |
| Beta | 1.22 |
| Outstanding Shares | 78,687,503 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.03 |
|---|---|
| PEG | -25.28 |
| Price to Sales | - |
| Price to Book Ratio | 3.84 |
| Enterprise Value to Revenue | 280.77 |
| Enterprise Value to EBIT | -7.19 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone